recently isolated a cDNA clone for the human cholecystokinin (CCK)B/gastrin receptor and permanently expressed this receptor cDNA in NIH-3T3 cells.
gastrointestinal tract, the CCKB/gastrin receptor plays an important role in gastric histamine release and acid secre tion (3) and enterochromaffin-like cell growth (4). These differences in pharmacological action aroused interest in antagonists for these subtypes, leading to the develop ment of benzodiazepine derivatives L-364,718 (5) and L-365,260 (6) as selective CCKA and CCKB/gastrin an tagonists, respectively.
We synthesized YM022 as a more potent and selective CCKB/gastrin-receptor ligand than L-365,260. YM022
replaces the specific binding of radiolabeled ligand to rat brain CCKB/gastrin receptor more potently than rat pan creatic CCKA receptor and inhibits pentagastrin-induced gastric acid secretion (7) and prevents gastric and duo denal lesions in rats (8) . These findings showed that YM022 acts as a selective rat CCKB/gastrin-receptor an tagonist both in vitro and in vivo and that this compound is a useful therapeutic agent for peptic ulcer disease.
Recently, the CCKB/gastrin receptors were cloned from human brain (9, 10) , dog parietal cells (11) , rat brain (12) and Mastomys natalensis enterochromaffin-like cells (13) . These receptors possess putative seven trans membrane domains, suggesting that they are rhodopsin type G protein-coupled receptors. Expression studies have revealed that both human and dog receptors gener ate phosphoinositide breakdown leading to intracellular Ca 2+ ([Ca 2+],) mobilization in response to a CCK agonist, CCK-8. Although the human and dog CCKB/gastrin receptors share 90% amino acid homology and have similar affinities for CCK-8, the binding of L-365,260 and L-364,718 to these receptors differs by up to 20-fold. This difference in binding is due to the substitution of a single amino acid in the sixth transmembrane domain only (14) . For the development of a human CCKB/gastrin receptor antagonist as an antiulcer drugs, it is therefore important to examine whether a CCKB/gastrin ligand exerts the same actions in both humans and other species.
To determine whether YM022 is an antagonist for both the human and rat CCKB/gastrin receptor, the functional human CCKB/gastrin-receptor cDNA isolated in our laboratory (15) Measurement of [Ca2+J; mobilization [Ca 2+]; in cells permanently expressing the human CCKB/gastrin receptor was measured by fura-2 fluo rometry. Cells cultured on a 13-mm diameter cover glass were loaded with 4 pM fura-2/AM in HEPES-buffered salt solution [HBSS: 20 mM HEPES (pH 7.4), 140 mM NaC1, 4 mM KC1, 1 mM K2HPO4i 1 MM MgC12, 1 MM CaC12, 10 mM glucose and 0.05% bovine serum albumin] for 30 min at 37C. After incubation, the cover glass was washed with HBSS and positioned in a quartz cuvette at 25 *C in a CAF/ 100 fluorescence spectrometer (Japan Spectroscopic Co., Tokyo). A final volume of 2 ml of HBSS with test reagents was stirred continuously at 1,000 rpm. The fluorescence was measured at excitation wavelengths of 340 and 380 nm and the emission wavelength of 500 nm. The level of [Ca 21], was calculated as described previously (17) . To elucidate whether the expressed human CCKB/gas trin receptor could couple to intracellular signaling, we examined the effect of CCK-8 on [Ca 2+], mobilization (Fig. 2) Using these functional human CCKB/gastrin receptor expressing cells, we investigated the pharmacological properties of YM022, a potent and selective CCKB/gas trin-receptor antagonist in rats (7) . Figure 3 
DISCUSSION
We have demonstrated that YM022, a rat CCKB/gas trin antagonist, is also a potent antagonist for human CCKB/gastrin receptor permanently expressed in NIH 3T3 cells. Preliminary experiments revealed that CCK-8 induced [Ca 2+], mobilization in dihydrofolate reductase deficient CHO cells but not in NIH-3T3 cells, which was consistent with a previous report (18) . We therefore transfected the human CCKB/gastrin-receptor cDNA iso lated in our laboratory (15) CCKB/gastrin receptors have been cloned from hu mans (9, 10), rats (11), dogs (12) and Mastomys natalensis (13) . All were shown to belong to a family of G protein coupled receptors. It has been suggested that the ligand binding sites of G protein-coupled receptors exist within transmembrane domains. Importantly, recent develop ments in molecular biology have revealed that a single amino acid difference in the transmembrane domains can cause pharmacological variation between species of G protein-coupled receptors, such as 5-HTIB (19) and NK1 (20) . Meanwhile, Beinborn et al. (14) clearly demon strated a difference in ligand binding properties between human and dog CCKB/gastrin receptors by transient expression of these receptors in COS cells. The human receptor binds L-365,260 with higher affinity than L 364,718 (IC50=4.5 nM vs 147 nM, respectively), whereas in the dog receptor, this order of affinity is reversed (IC50=80 nM vs 14 nM, respectively). The single amino acid substitution of valine in the sixth transmembrane domain of human receptor with a leucine, a dog count erpart, changes the binding property of the human recep tor to that of the dog (14) . The rat CCKB/gastrin recep tor, with a valine residue at this site, has higher affinity for L-365,260 than L-364,718 (6). These observations correlate well with the previous in vivo data that L 365,260 inhibited gastrin-stimulated acid secretion more strongly in rats than in dogs (6) . Judging from the similarity in pharmacological properties and benzodiaz epine structure, the valine residue in the sixth transmem brane domain may be essential for YM022 and L-365,260 binding to the human and rat CCKB/gastrin receptors.
Comparison of the cDNA sequences of human and rat CCKB/gastrin receptor shows that seven amino acids are different in their transmembrane domains. In the present study, these differences did not cause a dramatic change in affinity for CCK ligands similar to that above.
However, the different residue(s) appeared to determine the stereoselectivity of YM022. YM022 and its S-isomer displaced [125I]CCK-8 specific binding to human CCKB /gastrin receptor with IC50 values of 55 pM and 11 nM, respectively. This stereo selectivity was firmly supported by the finding that the affinity of the racemate (IC50=110 pM) was half that of YM022. We previously reported that YM022 and its racemate had the same affinity in the rat receptor as in the human homologue, with K, values of 68 and 110 pM, respectively, but that its S-isomer (K; = 140 nM) had less affinity (7) . The isomeric activity ra tios of YM022 in the human and rat receptor were 200 and 2,100, respectively. In addition to stereoselectivity, ligand specificity was also slightly different between hu man and rat CCKB/gastrin receptors. L-365,260 inhibited [125I1CCK-8 binding to human CCKB/gastrin receptor with an IC50 of 1.8 nM (Fig. 1 and Table 1) ; the inhibi tory activity ratio of L-365,260 to YM022 was 33, which is one order smaller than the 279 obtained in rat receptor (7) . Furthermore, the ratios of L-364,718 to L-365,260 were 21 and 105 in the human (Table 1 ) and rat (7) recep tors, respectively. These results are well-consistent with the ratios of 22 and 33 reported in the human receptor expressed in COS cells (14, 15) and the ratio of 125 in the rat brain receptor (6) . These values are summerized in Table 2 . Although it remains to be clarified which resi due(s) are involved in the stereo selectivity of YM022 or in the specificity of the antagonists, the human CCKB /gastrin receptor-expressing NIH-3T3 cells established in the present study are useful for the development of human CCKB/gastrin ligands. (4) , hypergastrinemia causes the relapse of pep tic ulcer. It has been reported that treatment with a pro ton pump inhibitor induced gastric lesions and hyper plasia of enterochromaffin-like cells (21 -23) and that these were inhibited by the CCKB/gastrin antagonist PD136540 in rats (24). Taken together, these observations suggest that CCKB/gastrin antagonists may prevent the relapse of peptic ulcers during therapy with the above an tisecretory drugs.
We recently reported that the oral administration of YM022 in rats inhibited gastrin-induced acid secretion and gastric and duodenal lesion formation (7, 8) . Furthermore, the affinity of YM022 for rat brain CCKB /gastrin receptor was 930 times greater than that for rat pancreatic CCKA receptor (7) . The present study demon strates that YM022 is also a potent human CCKB/gastrin antagonist. These findings suggest that YM022 may be a useful drug for patients with peptic ulcer accompanied by hypergastrinemia without side effects on the CCKA recep tor.
